Anders  Ullman net worth and biography

Anders Ullman Biography and Net Worth

Director of Verona Pharma
Since 2016, he has served as Head of the COPD Centre at Sahlgrenska University Hospital, Sweden. From 2013 to 2014, Dr Ullman was Executive Vice President and Head of Research and Development in the BioScience business unit of Baxter International, a healthcare company that became Baxalta. From 2007 to 2013, Dr Ullman was Executive Vice President, Head of Research and Development at Nycomed Pharma, which was acquired by Takeda Pharmaceutical. Dr Ullman received a MD and a PhD in clinical pharmacology from the University of Gothenburg.

How do I contact Anders Ullman?

The corporate mailing address for Mr. Ullman and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Anders Ullman's contact information.

Has Anders Ullman been buying or selling shares of Verona Pharma?

Anders Ullman has not been actively trading shares of Verona Pharma over the course of the past ninety days. Most recently, Anders Ullman sold 12,056 shares of the business's stock in a transaction on Tuesday, May 4th. The shares were sold at an average price of $0.84, for a transaction totalling $10,127.04. Learn More on Anders Ullman's trading history.

Who are Verona Pharma's active insiders?

Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.

Are insiders buying or selling shares of Verona Pharma?

In the last year, Verona Pharma insiders bought shares 2 times. They purchased a total of 193,736 shares worth more than $378,874.24. In the last year, insiders at the sold shares 19 times. They sold a total of 2,164,281 shares worth more than $13,411,301.36. The most recent insider tranaction occured on November, 20th when Director Martin Edwards bought 33,736 shares worth more than $62,074.24. Insiders at Verona Pharma own 4.8% of the company. Learn More about insider trades at Verona Pharma.

Information on this page was last updated on 11/20/2023.

Anders Ullman Insider Trading History at Verona Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/4/2021Sell12,056$0.84$10,127.04View SEC Filing Icon  
2/1/2021Sell10,800$0.99$10,692.00View SEC Filing Icon  
See Full Table

Anders Ullman Buying and Selling Activity at Verona Pharma

This chart shows Anders Ullman's buying and selling at Verona Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma Company Overview

Verona Pharma logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $16.09
Low: $15.80
High: $16.73

50 Day Range

MA: $16.95
Low: $15.30
High: $19.07

2 Week Range

Now: $16.09
Low: $11.83
High: $23.81

Volume

309,348 shs

Average Volume

433,598 shs

Market Capitalization

$1.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42